G Protein News and Research

RSS

Rice researchers describe a new method to predict the efficacy of H1N1 vaccines

As manufacturers work furiously to make a vaccine to protect against 2009 influenza A (H1N1) virus, a Rice University bioengineer is trying to improve the process for future flu seasons. The goal is to shorten the time it takes to identify targeted flu strains and manufacture the vaccines for them.

9 Sep 2009

Cell Biosciences acquires Alpha Innotech for $17.9 million

Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.

9 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

Roche RTS Protein Expression portfolio transferred to RiNA GmbH

Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009.

8 Sep 2009

BEST bags orders for state-of-the-art synchrotron instrumentation

Bruker Energy & Supercon Technologies, Inc. (BEST) today announced that its subsidiary Bruker ASC GmbH in Bergisch Gladbach, Germany, has been awarded several significant contracts for state-of-the-art synchrotron instrumentation from leading research institutions worldwide.

8 Sep 2009

Proteostasis Therapeutics to use GeneGo's MetaCore integrated software

GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases.

8 Sep 2009

Impact Fusion International completes geographic market test of Intact Digest

Impact Fusion International announced today it has successfully completed a limited geographic market test for Intact Digest with several retail vitamin stores re-ordering on a monthly basis.

8 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Researchers discover benefits of treating Alzheimer's disease with cancer drug

A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of the Journal of Alzheimer's Disease: Volume 18:1.

8 Sep 2009

Small molecule inhibitors could create new combination therapies

Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have confirmed that IPA-3, a small molecular inhibitor of a kinase called PAK1, targets the enzyme's regulatory domain, mimicking how enzymes are naturally regulated within cells.

8 Sep 2009

Aquaculture supplies half of the total fish and shellfish for human consumption

Aquaculture, once a fledgling industry, now accounts for 50 percent of the fish consumed globally, according to a new report by an international team of researchers. And while the industry is more efficient than ever, it is also putting a significant strain on marine resources by consuming large amounts of feed made from wild fish harvested from the sea, the authors conclude.

8 Sep 2009

COPD patients to have better protection against pneumonia with new vaccine

A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

8 Sep 2009

Small molecule blocks aberrant pathway associated with myotonic dystrophy

Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.

8 Sep 2009

Scientists solve the mystery of zonulin's identity

It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.

8 Sep 2009

Cognitive abilities decline more for people with Alzheimer's disease due to infections

Getting a cold, stomach bug or other infection may lead to increased memory loss in people with Alzheimer's disease, according to research published in the September 8, 2009, print issue of Neurology-, the medical journal of the American Academy of Neurology.

8 Sep 2009

Iterative in situ click chemistry creates antibody-like protein-capture agents

Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.

7 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

Identifying a specific molecular signature can help customize cancer treatment

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.

7 Sep 2009

Manuka honey inhibits MRSA infections by killing bacterial proteins

Manuka honey may kill bacteria by destroying key bacterial proteins. Dr Rowena Jenkins and colleagues from the University of Wales Institute - Cardiff investigated the mechanisms of manuka honey action and found that its anti-bacterial properties were not due solely to the sugars present in the honey.

7 Sep 2009

Harmless shard from childhood virus shell may halt biological process

A harmless shard from the shell of a common childhood virus may halt a biological process that kills a significant percentage of battlefield casualties, heart attack victims and oxygen-deprived newborns, according to research presented Sunday, September 6, 2009, at the 12th European meeting on complement in human disease in Budapest, Hungary.

7 Sep 2009